Holen Sie sich die Stockscreener-App
19.27
2.82%
-0.56
Handel nachbörslich:
19.27
Schlusskurs vom Vortag:
$19.83
Offen:
$19.86
24-Stunden-Volumen:
759.04K
Relative Volume:
0.57
Marktkapitalisierung:
$1.03B
Einnahmen:
$59,000
Nettoeinkommen (Verlust:
$-84.74M
KGV:
-3.3097
EPS:
-5.8222
Netto-Cashflow:
$-59.69M
1W Leistung:
-3.41%
1M Leistung:
+4.50%
6M Leistung:
+18.95%
1J Leistung:
+95.04%
1-Tages-Spanne:
$18.88
$19.86
1-Wochen-Bereich:
$18.88
$21.02
52-Wochen-Spanne:
$8.65
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Firmenname
Avalo Therapeutics Inc
Sektor
Branche
Telefon
410-522-8707
Adresse
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
19.27 | 1.06B | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-04-06 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-09-17 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-05 | Eingeleitet | TD Cowen | Buy |
| 2025-08-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-25 | Eingeleitet | Jefferies | Buy |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-28 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-21 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-10-24 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-04-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) insider to sell shares - Stock Titan
AVTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.83 Per Share Highlights Clinical-Stage BurnRevenue Growth Report - Vinanet
Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold - marketbeat.com
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock By Investing.com - Investing.com Australia
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock - Investing.com
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results - Stocktwits
Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX? - StockInvest.us
Avalo Therapeutics (AVTX): Nantahala Capital discloses 3.54% ownership stake - Stock Titan
Caligan Partners (NASDAQ: AVTX) reports 5.9% Avalo Therapeutics ownership on amended 13G - Stock Titan
RA Capital discloses 3.48M-share Avalo Therapeutics (AVTX) position in latest filing - Stock Titan
Avalo Therapeutics (AVTX): BVF group discloses 5.3% beneficial ownership stake - Stock Titan
Avalo Therapeutics (AVTX) sees T. Rowe Price report 3,670-share holding - Stock Titan
Avalo Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | C6K0 | US05338F3064 - marketscreener.com
Avoro Capital and Behzad Aghazadeh report 4.44% AVTX stake in 13G/A filing - Stock Titan
Deep Track Capital (AVTX) discloses 3.61M-share, 6.87% stake in Avalo - Stock Titan
Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (AVTX) sees 5.5% stake reported by Affinity Asset Advisors and Michael Cho - Stock Titan
Avalo Therapeutics (AVTX) Chief Strategy Officer Jennifer Riley Sells 2,655 Shares - GuruFocus
Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares - Stock Titan
Avalo Therapeutics (AVTX) CSO Riley sells 2,655 shares at about $19.59 - Stock Titan
Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC - MarketBeat
Avalo Therapeutics (AVTX) insider plans NASDAQ resale of 2,655 ESPP shares - Stock Titan
Equities Analysts Issue Forecasts for AVTX Q3 Earnings - MarketBeat
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy? - Yahoo Finance
Avalo Therapeutics (AVTX) insider schedules 679-share stock sale after option exercise - Stock Titan
Avalo Therapeutics (AVTX) Holds Near $18.29 as Shares Consolidate in a Narrow Trading BandSentiment Extreme - dars.gov.et
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail
Avalo Therapeutics (NASDAQ:AVTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $30 to $58 - Moomoo
AVTX Maintains Buy Rating by Guggenheim -- Price Target Lowered to $48 - GuruFocus
Avalo Therapeutics Inc (AVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC discloses 10.8% Avalo Therapeutics (AVTX) holding in Schedule 13G/A - Stock Titan
AVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
HC Wainwright Has Lowered Expectations for Avalo Therapeutics (NASDAQ:AVTX) Stock Price - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
AVTX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Issues Quarterly Earnings Results, Misses Expectations By $0.27 EPS - MarketBeat
Finanzdaten der Avalo Therapeutics Inc-Aktie (AVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):